Tumor and patient characteristics are classical factors that drive breast cancer therapy and predict prognosis together with the status of specific biomarkers, such as estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). Here, ERBB2 is linked to breast carcinoma.